Targeting of antithrombin in hemophilia A or B with RNAi therapy

New England Journal of Medicine

Volumn 377, Issue 9, 2017, Pages 819-828

  Pasi, K J ^a   Rangarajan, S ^f   Georgiev, P ^k   Mant, T ^b,g   Creagh, M D ^h   Lissitchkov, T ^l   Bevan, D ^c   Austin, S ^d   Hay, C R ⁱ   Hegemann, I ⁿ   Kazmi, R ^j   Chowdary, P ^e   Gercheva Kyuchukova, L ^m   Mamonov, V ^o   Timofeeva, M ^p   Soh, C H ^q   Garg, P ^q   Vaishnaw, A ^q   Akinc, A ^q   Sorensen B ^q,r   Ragni, M V ^s   more..

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^g IQVIA   (United States)

^h ROYAL CORNWALL HOSPITALS NHS TRUST   (United Kingdom)

ⁱ MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^j UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^k MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

^l UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^m UNIVERSITY HOSPITAL ST MARINA   (Bulgaria)

ⁿ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^o NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^p Kirov Research Institute of Hematology and Blood Transfusion   (Russian Federation)

^q ALNYLAM PHARMACEUTICALS   (United States)

^r Codiak Biosciences ^*  (United States)

^s UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; FITUSIRAN; PLACEBO; THROMBIN; ANTITHROMBIN III; SERPINC1 PROTEIN, HUMAN;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; HEADACHE; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS C; HUMAN; HUMAN EXPERIMENT; HYPERTRIGLYCERIDEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; LIMB PAIN; MALE; MULTICENTER STUDY; NORMAL HUMAN; OSTEOARTHRITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RNAI THERAPEUTICS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; THORAX PAIN; THROMBOEMBOLISM; TOOTH FRACTURE; TOOTH PAIN; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRUS PNEUMONIA; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADULT; ANTITHROMBIN III; ANTITHROMBINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEALTHY VOLUNTEERS; HEMOPHILIA A; HEMOPHILIA B; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RNAI THERAPEUTICS; SINGLE-BLIND METHOD; THROMBIN; YOUNG ADULT;

EID: 85028558994     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1616569     Document Type: Article

References (32)

1. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003;361:1801-9.
2. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012;379:1447-56.
3. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients — a long-term follow-up. J Intern Med 1997;241:395-400.
4. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232:25-32.
5. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011;9:700-10.
6. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44.
7. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013;19(1):e1-e47.
8. Berntorp E, Astermark J, Björkman S, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003;9:Suppl 1: 1-4.
9. Negrier C, Young G, Abdul Karim F, et al. Recombinant long-acting glyco-PEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials. Haemophilia 2016;22:507-13.
10. Young G, Collins PW, Colberg T, et al. Nonacog beta pegol (N9-GP) in haemophilia B: a multinational phase III safety and efficacy extension trial (Paradigm 4). Thromb Res 2016;141:69-76.
11. den Uijl IE, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia 2011;17:41-4.
12. Skinner MW. WFH: closing the global gap — achieving optimal care. Haemophilia 2012;18:Suppl 4:1-12.
13. Peters RT, Toby G, Lu Q, et al. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J Thromb Haemost 2013;11:132-41.
14. Ryan SM, Mantovani G, Wang X, Haddleton DM, Brayden DJ. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin Drug Deliv 2008;5:371-83.
15. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008; 132:171-83.
16. Mahdi AJ, Obaji SG, Collins PW. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Br J Haematol 2015;169:768-76.
17. Peyvandi F, Garagiola I, Biguzzi E. Advances in the treatment of bleeding disorders. J Thromb Haemost 2016;14: 2095-106.
18. Young G, Mahlangu JN. Extended half-life clotting factor concentrates: results from published clinical trials. Haemophilia 2016;22:Suppl 5:25-30.
19. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet 2016;388:187-97.
20. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138:305-15.
21. Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013;121:4046-55.
22. Shetty S, Vora S, Kulkarni B, et al. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol 2007;138:541-4.
23. Ghosh K, Shetty S, Mohanty D. Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as measured by one-stage assay. Haemophilia 2001;7:9-12.
24. Franchini M, Montagnana M, Targher G, et al. Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia. Semin Thromb Hemost 2009;35:307-12.
25. Negrier C, Berruyer M, Durin A, Philippe N, Dechavanne M. Increased thrombin generation in a child with a combined factor IX and protein C deficiency. Blood 1993;81:690-5.
26. Bolliger D, Szlam F, Suzuki N, Matsushita T, Tanaka KA. Heterozygous antithrombin deficiency improves in vivo hae-mostasis in factor VIII-deficient mice. Thromb Haemost 2010;103:1233-8.
27. Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015;21:492-7.
28. Hemker HC, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006;96:553-61.
29. Dargaud Y, Béguin S, Lienhart A, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005;93:475-80.
30. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 2005;172:367-79.
31. Inglesby TV, Rai R, Astemborski J, et al. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999;29:590-6.
32. Oh RC, Hustead TR. Causes and evaluation of mildly elevated liver transami-nase levels. Am Fam Physician 2011;84: 1003-8.